Skip to main content
. 2018 Mar 3;78(4):463–478. doi: 10.1007/s40265-018-0881-y

Fig. 4.

Fig. 4

Switching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropenia